scholarly journals Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium

2020 ◽  
Author(s):  
Rami S. Komrokji ◽  
Najla H Al Ali ◽  
David Sallman ◽  
Eric Padron ◽  
Amy E. DeZern ◽  
...  
Keyword(s):  
Clinical Research ◽  
Myelodysplastic Syndromes ◽  
Working Group ◽  
Response Criteria ◽  
International Working Group ◽  
Group Response ◽  
Research Consortium

scholarly journals Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Blood ◽  
2019 ◽  
Vol 133 (10) ◽  
pp. 1020-1030 ◽  
Author(s):  
U. Platzbecker ◽  
P. Fenaux ◽  
L. Adès ◽  
A. Giagounidis ◽  
V. Santini ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Myelodysplastic Syndromes ◽  
Working Group ◽  
Lower Risk ◽  
Response Assessment ◽  
Response To Treatment ◽  
Response Criteria ◽  
Patient Response ◽  
Erythroid Response ◽  
Clinical Responses

Abstract The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group (IWG) proposed a revision to previously published standardized response criteria (IWG 2000) for uniformly evaluating clinical responses in MDSs. These IWG 2006 criteria have been used prospectively in many clinical trials in MDSs, but proved challenging in several of them, especially for the evaluation of erythroid response. In this report, we provide rationale for modifications (IWG 2018) of these recommendations, mainly for “hematological improvement” criteria used for lower-risk MDSs, based on recent practical and reported experience in clinical trials. Most suggestions relate to erythroid response assessment, which are refined in an overall more stringent manner. Two major proposed changes are the differentiation between “procedures” and “criteria” for hematologic improvement–erythroid assessment and a new categorization of transfusion-burden subgroups.

scholarly journals International Myeloma Working Group response criteria

2019 ◽  
Author(s):  
Patrick Rock ◽  
Francis Deng
Keyword(s):  
Working Group ◽  
Response Criteria ◽  
Group Response ◽  
International Myeloma Working Group

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

2018 ◽  
Vol 18 (8) ◽  
pp. 528-532 ◽  
Author(s):  
Yazan Migdady ◽  
John Barnard ◽  
Najla Al Ali ◽  
David P. Steensma ◽  
Amy DeZern ◽  
...  
Keyword(s):  
Clinical Research ◽  
Clinical Outcomes ◽  
Myelodysplastic Syndromes ◽  
Ring Sideroblasts ◽  
Research Consortium

320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM

2015 ◽  
Vol 39 ◽  
pp. S158-S159 ◽  
Author(s):  
R. Komrokii ◽  
A. Zeidan ◽  
N. Al Ali ◽  
E. Padron ◽  
J. Lancet ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Clinical Research ◽  
Myelodysplastic Syndromes ◽  
Research Consortium

scholarly journals Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in Myelodysplastic Syndrome: Comparison With International Working Group Treatment Response Criteria

2016 ◽  
Vol 140 (6) ◽  
pp. 560-569 ◽  
Author(s):  
Jae Hyeon Park ◽  
Miyoung Kim ◽  
Sun-Young Kong ◽  
Sung-Soo Yoon ◽  
Dong Soon Lee
Keyword(s):  
In Situ Hybridization ◽  
Myelodysplastic Syndrome ◽  
Fluorescence In Situ Hybridization ◽  
Working Group ◽  
Initial Diagnosis ◽  
Response Criteria ◽  
Clone Size ◽  
International Working Group

At the initial diagnosis of myelodysplastic syndrome (MDS) and/or during follow-up, the evaluation of chromosomal abnormalities is based on standard G-banding, whereas the utility of fluorescence in situ hybridization (FISH) is still debated.Context.— To investigate whether interphase fluorescence in situ hybridization (iFISH) clone size at initial diagnosis of MDS is correlated with survival and whether changes in clonal fraction by iFISH are concordant with the MDS International Working Group response criteria during follow-up.Objectives.— A tailored FISH panel (−5/5q−, −7/7q−, +8, −20/20q−, and +1/1q+), based on reported cytogenetic changes in Korean patients with MDS, was performed in 81 patients with MDS at initial diagnosis and in 28 patients during follow-up.Design.— During follow-up, absolute increases in the clone size by iFISH by 20% or more, with relative increases of 50% or more, compared with previous specimens, were associated with transformation to acute myeloid leukemia (P = .001 and P = .002, respectively). Of the 28 patients with abnormal iFISH results, 7 (25%) showed discordance between iFISH and MDS International Working Group responses. Concordance between clone size by G-banding and iFISH was higher in the refractory cytopenia with unilineage dysplasia/refractory cytopenia with multilineage dysplasia group during follow-up, whereas the group with refractory anemia with excess blasts showed higher correlation at initial diagnosis.Results.— We conclude that iFISH can provide additional prognostic information and can predict the response to therapy in MDS.Conclusions.—

Sign in / Sign up

Export Citation Format

Share Document